Semaglutide Side Effects: The Complete 2026 Guide to Managing Every Symptom
Every semaglutide side effect ranked by frequency, explained with STEP trial data, and paired with specific management strategies — so you know exactly what to expect and how to stay on track.
More on Side Effects
Side effects are the single most common reason patients consider stopping semaglutide — and also the most preventable source of early discontinuation. Understanding what to expect, when symptoms peak, and what actually works to manage them can mean the difference between achieving meaningful weight loss and quitting in week three. This guide draws on the five published STEP clinical trials and post-approval pharmacovigilance data to give you the most complete, evidence-based picture of semaglutide's side-effect profile available in 2026.
The headline number — that 44% of STEP 1 participants reported nausea — is real, but the context around it matters enormously. That figure includes every patient who experienced nausea even once during the 68-week trial, including transient nausea lasting a single afternoon. When you look at discontinuation due to GI side effects, the rate drops to approximately 4.5% across the STEP program. The vast majority of patients tolerate semaglutide and complete treatment. For a broader comparison of tolerability across medications, see our guide to GLP-1 medications with the fewest side effects.
The strategies covered in this guide — from meal timing and dietary adjustments to dose titration modifications and when to involve your provider — are grounded in clinical practice patterns that have helped thousands of patients stay on therapy. If you are already on semaglutide and struggling, this guide will help you identify whether what you are experiencing is typical, manageable, or worth a provider conversation. If you are considering starting, it will help you prepare proactively. For Trimi members, your provider team is available to support you through every stage of the titration process.
Complete Side Effects Frequency Table (STEP Trial Data)
The following table summarizes adverse events from the STEP 1 trial (Wilding et al., NEJM 2021), the largest semaglutide weight-management trial with 1,961 participants. Frequencies represent the percentage of patients reporting each event at any point during 68 weeks of treatment at the 2.4 mg maintenance dose.
| Side Effect | Semaglutide 2.4 mg | Placebo | Classification | When It Peaks |
|---|---|---|---|---|
| Nausea | 44.2% | 16.1% | Very Common | Weeks 1–16 (dose escalation) |
| Diarrhea | 29.7% | 15.9% | Very Common | Weeks 1–8, can recur at dose steps |
| Vomiting | 24.8% | 6.8% | Very Common | Weeks 1–16, especially after dose increase |
| Constipation | 24.2% | 11.1% | Very Common | Throughout treatment, esp. maintenance phase |
| Abdominal Pain | 19.9% | 9.4% | Common | Variable; can occur throughout |
| Headache | 13.6% | 10.2% | Common | Weeks 1–4, often transient |
| Fatigue | 11.2% | 6.6% | Common | Weeks 1–8; often parallels caloric restriction |
| Dyspepsia / Indigestion | 9.2% | 4.6% | Common | Variable; worsens with trigger foods |
| Belching / Flatulence | 6.8% | 2.8% | Common | Weeks 1–12 |
| Gallbladder Events | 2.6% | 1.2% | Uncommon | Any time; higher risk with rapid weight loss |
| Pancreatitis | <0.2% | <0.1% | Rare — Monitor | Any time; call doctor immediately |
| Injection Site Reactions | 3.1% | 2.0% | Uncommon | Within 24–48 h of injection |
| Hair Loss (Telogen Effluvium) | 3.0% | 1.0% | Uncommon | Months 2–6 (related to caloric deficit) |
Sources: Wilding JPH et al. NEJM 2021 (STEP 1); Davies M et al. NEJM 2021 (STEP 2); Wadden TA et al. NEJM 2021 (STEP 3); Rubino D et al. JAMA 2021 (STEP 4); Colhoun HM et al. Lancet 2023 (STEP 5). Frequencies from STEP 1 at 2.4 mg weekly vs. placebo.
Symptom-by-Symptom Management Guide
Nausea (44% of patients)
Nausea is caused by semaglutide's action on GLP-1 receptors in the gut and brain, which slows gastric emptying and activates nausea centers in the brainstem. It is almost always most severe during dose escalation steps and diminishes once your body adapts to each new dose level. For most patients, nausea becomes manageable or disappears entirely within 4 to 6 weeks of reaching the maintenance dose.
Management strategies:
- Eat small, frequent meals — 4 to 6 small meals daily rather than 2 to 3 large ones. Overloading an already-slow stomach is the primary trigger.
- Avoid high-fat, fried, and spicy foods — these slow gastric emptying further and amplify nausea. Bland, lean, lightly seasoned foods are best during dose escalation.
- Time your injection at bedtime — injecting before sleep allows you to rest through the 4- to 8-hour window of peak drug concentration when nausea is most likely.
- Try ginger — ginger tea, ginger chews, or ginger capsules have good evidence for mild-to-moderate nausea and are safe to use alongside semaglutide.
- Stay upright after eating — lying down immediately after meals worsens gastroparesis symptoms. Wait at least 90 minutes before lying down.
- Ask your provider about antiemetics — ondansetron (Zofran) is commonly prescribed for severe titration-phase nausea and is safe to use short-term.
- Consider a slower titration schedule — extending each dose step from 4 weeks to 6 or 8 weeks can dramatically reduce peak nausea while still reaching the therapeutic dose. Discuss this option with your Trimi provider.
For a comprehensive nausea management approach, see our complete guide to stopping semaglutide nausea.
Diarrhea (30% of patients)
Diarrhea on semaglutide typically results from accelerated transit in parts of the gut, increased gut motility stimulated by GLP-1 receptors in the intestinal wall, and changes in bile acid metabolism. It tends to cluster in the first 8 weeks but can recur with each dose increase. Most episodes are mild, self-limiting, and resolve within a day or two.
Management strategies:
- Prioritize hydration and electrolytes — diarrhea is the fastest route to dehydration on semaglutide. Sip water and electrolyte drinks (avoid sugary sports drinks) throughout the day.
- Follow the BRAT approach during acute episodes — bananas, rice, applesauce, and toast are easy on the gut during flare-ups.
- Limit artificial sweeteners, sorbitol, and caffeine — these act as osmotic laxatives and can worsen semaglutide-related diarrhea significantly.
- Consider soluble fiber — psyllium husk can help normalize stool consistency by absorbing excess water without stimulating additional gut motility.
- Use loperamide (Imodium) for breakthrough episodes — safe for short-term use when diarrhea is disruptive. Do not use if fever or blood in stool is present.
Constipation (24% of patients)
Constipation is the flip side of diarrhea and, for many patients, becomes more prevalent than diarrhea once they reach higher doses. Semaglutide's gastroparesis effect — slowing stomach emptying — extends throughout the GI tract for some patients, reducing overall transit speed. Reduced food intake also means less bulk to stimulate bowel movements. Constipation is the side effect most likely to persist throughout the entire treatment course rather than resolving after titration.
Management strategies:
- Increase dietary fiber incrementally — aim for 25–35 g of fiber daily from vegetables, legumes, and whole grains. Add slowly to avoid bloating.
- Hydrate aggressively — fiber requires water to work. Target at least 64–80 oz of fluid daily, more if you are active or sweating.
- Add light daily movement — a 20-minute walk after meals stimulates intestinal motility more reliably than most laxatives.
- Try polyethylene glycol (MiraLAX) — osmotic laxatives are safe for regular use on semaglutide and are recommended by most GI specialists for medication-induced constipation.
- Consider magnesium citrate or magnesium glycinate — gentle osmotic effect with the added benefit of supporting sleep and reducing muscle cramps, which can also occur with caloric restriction.
Vomiting (25% of patients)
Vomiting is less common than nausea but significantly more disruptive when it occurs. It is most likely to happen in the 24 to 48 hours after a dose increase and is often triggered by eating too quickly, consuming rich or fatty foods, or drinking carbonated beverages. Repeated vomiting is medically important because it can lead to dehydration, electrolyte imbalances, and medication malabsorption.
Management strategies:
- Eat extremely slowly — take at least 20 minutes per meal. Eating rapidly overwhelms a slowed stomach and is the most preventable vomiting trigger.
- Avoid carbonated drinks — gas in a slow-emptying stomach creates pressure that can trigger the vomiting reflex.
- Stop eating at the first sign of fullness — semaglutide amplifies satiety signals significantly. Continuing to eat past early fullness often leads to vomiting.
- Contact your provider if vomiting prevents hydration for more than 24 hours — IV fluids may be necessary, and a temporary dose reduction should be considered.
Headache (14% of patients)
Headaches during semaglutide treatment are most common in the first 2 to 4 weeks and are often driven by reduced caloric intake, dehydration, and shifts in blood sugar levels rather than direct drug effects. They typically resolve within the first month and are rarely a persistent problem.
- Prioritize hydration — most medication-adjacent headaches are dehydration headaches.
- Ensure adequate electrolyte intake (sodium, potassium, magnesium) during early dose escalation.
- Avoid dropping calories too aggressively in the first month — a very low-calorie intake on top of reduced appetite can worsen headaches.
- Over-the-counter acetaminophen or ibuprofen is safe to use for breakthrough headaches unless contraindicated for another reason.
Fatigue (11% of patients)
Fatigue in the first 4 to 8 weeks of semaglutide treatment is almost always related to reduced caloric intake and the metabolic adjustment your body makes as it shifts from glucose to fat as a primary fuel source — not a direct drug effect. It can also be compounded by dehydration or poor protein intake. Persistent fatigue beyond 3 months, or fatigue that worsens rather than improves after stabilizing on a dose, should be evaluated.
- Maintain protein intake above 100 g daily — protein is the most fatigue-protective macronutrient during caloric restriction.
- Do not drop calories below 1,200 kcal/day without medical supervision — extremely low caloric intake dramatically worsens fatigue and muscle loss.
- Check iron, B12, and thyroid function if fatigue is significant — weight loss can unmask pre-existing nutritional deficiencies.
- Light exercise, counterintuitively, often reduces fatigue more than rest for patients on GLP-1 medications.
Abdominal Pain (20% of patients)
Abdominal pain on semaglutide is most often cramping or bloating associated with GI motility changes — a direct consequence of slowed gastric emptying and altered intestinal transit. This type of pain is typically mild, cramp-like, and positional (worse after eating). It is distinct from the serious abdominal pain of pancreatitis, which is severe, persistent, and radiates to the back.
Important: Mild, crampy abdominal pain after eating is common and manageable. Severe, persistent abdominal pain — especially pain that radiates to your back or is accompanied by fever — requires immediate medical evaluation to rule out pancreatitis or gallbladder disease.
- For mild cramping: small meals, avoiding gas-producing foods, and peppermint tea or peppermint capsules can provide significant relief.
- Antacids (calcium carbonate) or simethicone can help reduce gas-related pain and bloating.
- If pain is consistently severe or worsening, contact your provider before the next scheduled check-in.
Dose-Dependent Side Effects: What Changes at Each Step
Semaglutide for weight management follows a standard titration schedule: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with 4 weeks at each dose. Side effects are not uniform across this schedule — they are tightly tied to when dose increases occur. Understanding this pattern lets you anticipate difficult periods and prepare proactively.
| Dose | Timeline | Expected Side Effects | What Helps |
|---|---|---|---|
| 0.25 mg | Weeks 1–4 | Mild nausea (first 1–3 days), reduced appetite, occasional headache | Bedtime injection, small meals, hydration |
| 0.5 mg | Weeks 5–8 | Increased nausea, possible diarrhea, appetite suppression strengthens | Extend to 6 weeks if needed, avoid fatty foods |
| 1.0 mg | Weeks 9–12 | Nausea often peaks here; constipation begins for many patients | Add fiber, MiraLAX, maintain protein intake |
| 1.7 mg | Weeks 13–16 | Second peak of GI symptoms, abdominal cramping possible | Slower titration option, peppermint, small meals |
| 2.4 mg (maintenance) | Week 17+ | Most patients see significant improvement; constipation may persist | Maintain fiber and hydration; check in with provider at month 6 |
An important clinical note: if side effects at any dose are intolerable, your provider can pause your titration — staying at the current dose for an extra 4 to 8 weeks — rather than escalating on schedule. This practice, known as extended titration, is widely used by experienced GLP-1 prescribers and has been shown to improve long-term treatment adherence without meaningfully reducing weight-loss outcomes. Trimi providers routinely offer individualized titration support to members who need it. If you are at a difficult dose transition, reach out through your Trimi provider dashboard rather than stopping the medication unilaterally.
For the complete dosing framework and how to navigate each step, see our semaglutide dosage guide, and for a comparison of how semaglutide's side-effect profile compares to tirzepatide at equivalent stages, see our tirzepatide vs semaglutide comparison.
When Semaglutide Side Effects Typically Resolve
Weeks 1–2: Initial Adjustment
The first injection often triggers the mildest side effects — reduced appetite, possibly mild nausea for 24 to 48 hours, occasional headache. Most patients find the first dose very manageable. The 0.25 mg starting dose is specifically designed to minimize early side effects.
Weeks 3–8: Dose Escalation Phase
This is when most patients experience their highest side-effect burden. Each new dose step creates a brief window of increased nausea, possible diarrhea, and sometimes fatigue. The period immediately after each dose increase (days 2–5 after injection) is typically the most symptomatic. By the end of week 8, most patients on the 0.5 mg dose have largely adapted.
Weeks 9–16: Higher Dose Transitions
The 1.0 mg and 1.7 mg steps are where many patients see a recurrence of GI symptoms that had settled down. Constipation often increases during this phase as gastric emptying slows further. Abdominal cramping can become more noticeable. This is the phase where proactive management (fiber, hydration, slower titration if needed) makes the biggest difference in treatment completion rates.
Months 4–6: Maintenance Stabilization
The majority of patients stabilized on 2.4 mg report a significant improvement in GI symptoms compared to their worst points during titration. Nausea is typically mild or absent. Diarrhea resolves for most patients. Constipation may persist and requires ongoing dietary management. Energy levels generally improve as the body fully adapts to the reduced caloric intake and higher fat utilization.
Months 6–18: Long-Term Treatment
Long-term side effects in the STEP 5 trial (2 years) showed that GI adverse events declined substantially after the 4-month mark and remained low through the second year of treatment. Persistent side effects beyond 6 months at a stable dose should be investigated rather than assumed to be drug-related. Hair thinning (telogen effluvium from caloric restriction) often peaks at 3 to 6 months and resolves spontaneously as the body adapts.
Serious Side Effects: When to Call Your Doctor Immediately
The serious adverse events associated with semaglutide are rare — but they require immediate medical evaluation when they occur. Unlike the GI side effects described above, these cannot be managed at home and should never be waited out. For a comprehensive overview of monitoring requirements, see our guide to lab monitoring on GLP-1 medications.
Acute Pancreatitis (<0.2% incidence)
GLP-1 receptor agonists including semaglutide carry a warning for acute pancreatitis. The incidence in the STEP trials was low (less than 0.2%), but the condition is serious and requires immediate hospitalization. The mechanism may involve increased pancreatic exocrine secretion and elevated triglyceride levels in some patients.
Call 911 or go to the emergency room immediately if you experience:
- • Severe, persistent abdominal pain (especially upper abdomen or radiating to the back)
- • Abdominal pain accompanied by fever, nausea, and vomiting that does not improve
- • Tenderness when touching the upper abdomen
If pancreatitis is confirmed, semaglutide must be permanently discontinued. Patients with a history of pancreatitis should discuss whether semaglutide is appropriate before starting.
Gallbladder Disease (2.6% incidence)
Gallbladder events — including cholelithiasis (gallstones), cholecystitis (gallbladder inflammation), and choledocholithiasis — were reported in 2.6% of STEP 1 participants compared to 1.2% in the placebo group. Rapid weight loss itself is a known risk factor for gallstone formation, as fat mobilization increases cholesterol concentration in bile. Semaglutide may also affect gallbladder motility directly through GLP-1 receptor activity.
Contact your provider promptly if you experience:
- • Severe right-sided upper abdominal or shoulder pain lasting more than a few hours
- • Pain after eating fatty foods (classic biliary colic pattern)
- • Jaundice (yellowing of skin or eyes), dark urine, or pale stools
- • Fever with abdominal pain
Patients with pre-existing gallbladder disease or a history of gallstones should discuss their individual risk with their provider before starting semaglutide.
Thyroid C-Cell Tumors (Black Box Warning)
Semaglutide carries a black box warning — the FDA's most serious warning level — for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This risk was identified in rodent studies where GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and tumors. The clinical relevance in humans remains uncertain; large-scale epidemiological studies have not confirmed an elevated risk of MTC in GLP-1 users, and thyroid C-cells in humans express lower levels of GLP-1 receptors than those in rodents.
Semaglutide is absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These patients should not use semaglutide or any GLP-1 receptor agonist.
Report to your provider promptly if you notice:
- • A new lump or swelling in the neck
- • Hoarseness or voice changes not explained by a cold
- • Difficulty swallowing
- • Shortness of breath
Other Serious Events to Know About
Severe Allergic Reactions (Rare)
Anaphylaxis and angioedema have been reported with semaglutide. If you experience swelling of the face, lips, tongue, or throat, hives, or difficulty breathing after an injection, call 911 immediately. Do not administer another dose.
Hypoglycemia (Mainly in Diabetic Patients on Insulin/Sulfonylureas)
Semaglutide alone rarely causes significant hypoglycemia. However, patients with type 2 diabetes who are also on insulin or sulfonylureas face a meaningfully elevated hypoglycemia risk when starting semaglutide, as the combined effects can drive blood sugar too low. Dose adjustments of concurrent diabetes medications are often needed. See our guide to semaglutide in type 2 diabetes.
Aspiration Risk During Procedures
Because semaglutide slows gastric emptying, patients should inform their anesthesiologist before any procedure requiring anesthesia or sedation. Current guidance from major anesthesiology societies recommends stopping GLP-1 medications for 1 week (weekly injections) before elective procedures to minimize aspiration risk.
Trimi's Provider Support for Side Effect Management
Side effect management is one of the most important services a good GLP-1 provider offers — and it is one of the most frequently underdelivered. Many patients struggle in silence with manageable symptoms because they do not know how to access their provider quickly enough, or because the provider's response time makes it impractical to get real-time guidance.
Trimi is built specifically around the kind of ongoing clinical support that makes GLP-1 treatment sustainable. Trimi members have access to licensed providers who specialize in GLP-1 therapy and are familiar with the full spectrum of side effects described in this guide. Support is available between scheduled appointments through the Trimi platform, so if you are three days into a new dose and struggling with nausea, you do not have to wait until next month's check-in to get guidance.
Titration Personalization
Trimi providers individualize titration schedules based on your tolerance at each dose step — extending to 6 or 8 weeks when needed, or pausing titration entirely if a dose step is causing significant side effects.
Prescription Support Medications
When OTC remedies are insufficient, Trimi providers can prescribe anti-nausea medications, laxatives, or other supportive therapies to help you stay on track through the most challenging titration phases.
Lab Monitoring Guidance
Trimi coordinates appropriate blood work to monitor for early signs of gallbladder, thyroid, or pancreatic issues, and to track metabolic improvements so you can see the full picture of what semaglutide is doing for your health. Learn more about what blood tests to get before starting GLP-1.
Switching Support
If semaglutide side effects prove intolerable despite all management strategies, Trimi providers can guide a transition to tirzepatide or assist with an ultra-slow titration protocol tailored to highly sensitive patients. See our tirzepatide side effects guide for comparison.
Struggling With Side Effects?
Trimi's licensed providers specialize in GLP-1 therapy and are available to support you through every stage of titration — not just at scheduled check-ins.
Get Provider SupportFrequently Asked Questions
What is the most common side effect of semaglutide?
Nausea is the most common side effect, reported by approximately 44% of participants in the STEP 1 trial at the 2.4 mg dose. It is most prevalent during the initial dose-escalation phase and typically improves once patients reach and stabilize on their maintenance dose. Most patients describe it as mild to moderate and manageable with dietary adjustments.
How long do semaglutide side effects last?
For most patients, gastrointestinal side effects like nausea and diarrhea are most intense during the first 4 to 8 weeks and improve substantially after reaching the maintenance dose. The STEP trials showed that nausea incidence dropped significantly after the titration phase ended, typically around week 16. Some patients experience occasional GI symptoms throughout treatment, but severe symptoms that persist beyond 3 months should be evaluated by a provider.
Does semaglutide nausea go away?
Yes, for the vast majority of patients. In the STEP trials, nausea was predominantly transient — occurring during dose escalation and resolving or becoming minimal once patients stabilized at their maintenance dose. Extending the time at each dose level (slower titration) is the most effective strategy for reducing nausea severity. Only about 5% of patients in clinical trials discontinued due to GI side effects.
Can semaglutide cause serious side effects?
Yes, though rare. Serious side effects include acute pancreatitis, gallbladder disease (including gallstones and cholecystitis), and — based on rodent studies — a theoretical risk of medullary thyroid carcinoma. Semaglutide carries a black box warning for thyroid C-cell tumors in patients with a personal or family history of medullary thyroid cancer or MEN2. Any severe persistent abdominal pain, jaundice, or new neck lump should be evaluated immediately.
How can I stop nausea from semaglutide?
The most effective strategies include eating smaller, more frequent meals; avoiding high-fat, fried, or heavily spiced foods; staying well hydrated; timing your injection before bed to sleep through peak nausea; and not escalating your dose faster than prescribed. Ginger tea or ginger chews can help mild nausea. If nausea is interfering with daily life, ask your provider about prescription anti-nausea medications like ondansetron or a temporary dose reduction.
Is semaglutide safe for the thyroid?
Semaglutide carries a black box warning for thyroid C-cell tumors based on animal studies. In rodents, GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. However, this has not been definitively demonstrated in humans, and population-based pharmacovigilance studies have not confirmed an elevated risk of medullary thyroid carcinoma in semaglutide users. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Any new neck lump, hoarseness, or difficulty swallowing should be reported to a provider promptly.
What dose of semaglutide has the most side effects?
Side effects are dose-dependent and most pronounced during dose escalation. The transition to higher doses — particularly the steps from 0.5 mg to 1.0 mg and from 1.7 mg to 2.4 mg — tend to trigger the most nausea and GI symptoms. In the STEP trials, patients on the highest dose (2.4 mg) experienced the highest overall rates of nausea (44%) and other GI side effects, though most were transient. Slowing the titration schedule can significantly blunt these effects.
Related Guides
Managing GI Side Effects on Semaglutide
Step-by-step guide to the most common gastrointestinal symptoms
How the titration schedule works and when to escalate
Diet choices that minimize nausea and support weight loss
Deep dive into the thyroid black box warning and what the evidence shows
Full comparison including side-effect profiles side by side
Prevention strategies and what to watch for
More on Side Effects
Sources & References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight (STEP 3). JAMA. 2021;325(14):1403-1413.
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity (STEP 8). JAMA. 2022;327(2):138-150.
- Colhoun HM, Lingvay I, Cesana F, et al. Long-term (2-year) safety of semaglutide 2.4 mg vs placebo in adults with overweight or obesity (STEP 5). Lancet Diabetes Endocrinol. 2023;11(5):333-345.
- FDA Prescribing Information: Wegovy (semaglutide) Injection 2.4 mg. Novo Nordisk. Revised 2024.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. Molecular Metabolism. 2018;18:3-14.
Medical Disclaimer
This article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Side-effect experiences vary significantly between individuals, and the frequencies cited here reflect population-level data from clinical trials, which may not reflect your personal experience. All decisions about starting, adjusting, or stopping semaglutide or any other medication should be made in consultation with a qualified, licensed healthcare provider who can evaluate your individual medical history, current medications, and clinical situation. Do not adjust your medication dose, titration schedule, or stop treatment without professional guidance.